CGEM insider buys total 1,459,641 shares across Oct 8–10
Rhea-AI Filing Summary
Lynx1 Capital Management LP and affiliated reporting person Weston Nichols disclosed purchases of Cullinan Therapeutics, Inc. (CGEM) common stock across three days. On 10/08/2025 they bought 556,300 shares at a weighted average price of $6.46, increasing indirect holdings to 7,645,743 shares. On 10/09/2025 they acquired 626,043 shares at a weighted average of $6.6958, bringing holdings to 8,271,786 shares. On 10/10/2025 they purchased 277,298 shares at a weighted average of $7.3617, raising indirect holdings to 8,549,084 shares. The shares are held directly by Lynx1 Master Fund LP, for which Lynx1 Capital Management LP serves as investment manager; the filing disclaims beneficial ownership except to the extent of any pecuniary interest.
Positive
- Material accumulation: 1,459,641 shares acquired over three days indicates meaningful fund-level buying
- Clear disclosure: Filing provides weighted-average prices and entity relationships, aiding transparency
Negative
- Indirect ownership held via Lynx1 Master Fund LP, with disclaimer of beneficial ownership limits clarity on direct economic interest
- No derivative activity reported, so leverage or hedging stance is not disclosed
Insights
Substantial insider-aligned fund purchases increased indirect stake to 8.55M shares.
The purchases occurred over 10/08/2025–10/10/2025 and were executed by Lynx1 entities, with the securities held directly by Lynx1 Master Fund LP. The filing clarifies the investment manager and general partner relationships and includes weighted-average prices for each trading day.
This structure means the trading reflects the fund's activity rather than direct personal buys; monitor subsequent Form 4 filings for any changes in ownership form or additional purchases within the next quarter to assess trend persistence.
Average purchase prices rose across three days, suggesting intra-day/market price movement.
The weighted-average prices moved from $6.46 to $6.6958 to $7.3617, indicating upward execution prices during the reported window. Total newly acquired shares equal 1,459,641.
If trading continued, short-term price impact could be observable; watch for additional volume disclosures or updated filings within 30 days that would show follow-on accumulation or disposition.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 277,298 | $7.3617 | $2.04M |
| Purchase | Common Stock | 626,043 | $6.6958 | $4.19M |
| Purchase | Common stock, $0.0001 par value per share ("Common Stock") | 556,300 | $6.46 | $3.59M |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.40 to $6.60 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. The securities to which this filing relates are held directly by Lynx1 Master Fund LP to which Lynx1 Capital Management LP (the "Investment Manager") serves as investment manager. Weston Nichols ("Mr. Nichols") is the sole member of Lynx1 Capital Management GP LLC, the general partner of the Investment Manager. Each of the Investment Manager and Mr. Nichols disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.60 to $6.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.87 to $7.46 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
